226 related articles for article (PubMed ID: 25567352)
1. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Giancotti FG; Filatov A; Derman A; Hochman T; Goldberg JD; Vega E; Wisoff JH; Golfinos JG; Merkelson A; Roland JT; Allen JC
Neuro Oncol; 2014 Jan; 16(2):292-7. PubMed ID: 24311643
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
4. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.
Goutagny S; Giovannini M; Kalamarides M
J Neurooncol; 2017 Jun; 133(2):443-445. PubMed ID: 28434114
[No Abstract] [Full Text] [Related]
5. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
9. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
[TBL] [Abstract][Full Text] [Related]
10. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Ballas MS; Brown K; Nusbaum AO; Hochman T; Goldberg JD; Koch KM; Golfinos JG; Roland JT; Allen JC
Neuro Oncol; 2012 Sep; 14(9):1163-70. PubMed ID: 22844108
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
[TBL] [Abstract][Full Text] [Related]
14. Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
Karajannis MA; Mauguen A; Maloku E; Xu Q; Dunbar EM; Plotkin SR; Yaffee A; Wang S; Roland JT; Sen C; Placantonakis DG; Golfinos JG; Allen JC; Vitanza NA; Chiriboga LA; Schneider RJ; Deng J; Neubert TA; Goldberg JD; Zagzag D; Giancotti FG; Blakeley JO
Mol Cancer Ther; 2021 Sep; 20(9):1584-1591. PubMed ID: 34224367
[TBL] [Abstract][Full Text] [Related]
15. Ataxia in a Young Female.
Jayanthi R; Monica K; Raja K; Gauthaman CS; Arunkumar PP
J Assoc Physicians India; 2017 Aug; 65(8):109-110. PubMed ID: 28799319
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after Gamma Knife surgery for vestibular schwannomas: a 10-year experience.
Liu D; Xu D; Zhang Z; Zhang Y; Zheng L
J Neurosurg; 2006 Dec; 105 Suppl():149-53. PubMed ID: 18503349
[TBL] [Abstract][Full Text] [Related]
18. Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2007 Dec; 28(8):1083-90. PubMed ID: 18043434
[TBL] [Abstract][Full Text] [Related]
19. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
20. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
